Oropram Filmuhúðuð tafla 10 mg Island - isländska - LYFJASTOFNUN (Icelandic Medicines Agency)

oropram filmuhúðuð tafla 10 mg

teva b.v.* - citalopram hydrobromide - filmuhúðuð tafla - 10 mg

Oropram Filmuhúðuð tafla 20 mg Island - isländska - LYFJASTOFNUN (Icelandic Medicines Agency)

oropram filmuhúðuð tafla 20 mg

teva b.v.* - citalopram hydrobromide - filmuhúðuð tafla - 20 mg

Oropram Filmuhúðuð tafla 40 mg Island - isländska - LYFJASTOFNUN (Icelandic Medicines Agency)

oropram filmuhúðuð tafla 40 mg

teva b.v.* - citalopram hydrobromide - filmuhúðuð tafla - 40 mg

Sinemet 12,5/50 Tafla 12,5 mg/50 mg Island - isländska - LYFJASTOFNUN (Icelandic Medicines Agency)

sinemet 12,5/50 tafla 12,5 mg/50 mg

n.v. organon* - carbidopum inn; levodopum inn - tafla - 12,5 mg/50 mg

Sinemet 25/100 Tafla 25 mg/100 mg Island - isländska - LYFJASTOFNUN (Icelandic Medicines Agency)

sinemet 25/100 tafla 25 mg/100 mg

n.v. organon* - levodopum inn; carbidopum inn - tafla - 25 mg/100 mg

Sinemet Depot Mite (Sinemet depot mite) Forðatafla 25 mg/100 mg Island - isländska - LYFJASTOFNUN (Icelandic Medicines Agency)

sinemet depot mite (sinemet depot mite) forðatafla 25 mg/100 mg

n.v. organon* - levodopum inn; carbidopum inn - forðatafla - 25 mg/100 mg

Orserdu Europeiska unionen - isländska - EMA (European Medicines Agency)

orserdu

stemline therapeutics b.v. - elacestrant - brjóstakrabbamein - innkirtla meðferð - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.

Daklinza Europeiska unionen - isländska - EMA (European Medicines Agency)

daklinza

bristol-myers squibb pharma eeig - daclatasvir díhýdróklóríð - lifrarbólga c, langvinn - veirueyðandi lyf til almennrar notkunar - daklinza er ætlað í samsettri meðferð með öðrum lyfjum til meðferðar við langvinna lifrarbólgu c veiru (hcv) sýkingu hjá fullorðnum (sjá kafla 4. 2, 4. 4 og 5. fyrir hcv arfgerð sérstakur starfsemi, sjáðu kafla 4. 4 og 5.

Epclusa Europeiska unionen - isländska - EMA (European Medicines Agency)

epclusa

gilead sciences ireland uc - sofosbuvir, velpatasvir - lifrarbólga c, langvinn - veirueyðandi lyf til almennrar notkunar - epclusa is indicated for the treatment of chronic hepatitis c virus (hcv) infection in patients 3 years of age and older (see sections 4. 2, 4. 4 og 5.

Harvoni Europeiska unionen - isländska - EMA (European Medicines Agency)

harvoni

gilead sciences ireland uc - ledipasvir, sofosbuvir - lifrarbólga c, langvinn - veirueyðandi lyf til almennrar notkunar - harvoni is indicated for the treatment of chronic hepatitis c (chc) in adult and paediatric patients aged 3 years and above (see sections 4. 2, 4. 4 og 5. fyrir lifrarbólgu c veira (hcv) arfgerð-sérstakur starfsemi sjá kafla 4. 4 og 5.